Inhalational delivery of IFN-γ in IPF has been assessed for safety, and is now being evaluated for a larger trial, with the goal of stimulating macrophages and inhibiting fibrosis via this cytokine (56, 57). This evidence concerns the gene IFNG and idiopathic pulmonary fibrosis.